UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Polycyclic aromatic hydrocarbons and risk of rheumatoid arthritis: a cross-sectional analysis of the National Health and Nutrition Examination Survey, 2007–2016

BMJ open, 2023-05, Vol.13 (5), p.e071514-e071514

2023

Volltextzugriff (PDF)

Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial

Alimentary pharmacology & therapeutics, 2018-06, Vol.47 (11), p.1453-1463

2018

Volltextzugriff (PDF)

AB0045 Activated rnase l as a novel disease activity biomarker in psoriatic arthritis

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1222

2018

Volltextzugriff (PDF)

Psoriatic arthritis screening tools: study design and methodological challenges

British journal of dermatology (1951), 2014-04, Vol.170 (4), p.994-995

2014

Volltextzugriff (PDF)

Adalimumab for treatment of pyoderma gangrenosum

British journal of dermatology (1951), 2007-12, Vol.157 (6), p.1274-1275

2007

Volltextzugriff (PDF)

POS1050 SECUKINUMAB LEADS TO IMPROVEMENT ACROSS PSORIATIC ARTHRITIS MANIFESTATIONS OVER 2 YEARS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR: A POST HOC ANALYSIS OF FUTURE 5

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.802-803

2021

Volltextzugriff (PDF)

Oral or transdermal opioids for osteoarthritis of the knee or hip

Cochrane database of systematic reviews, 2014-09, Vol.2014 (9), p.CD003115

2014

Volltextzugriff (PDF)

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis

The New England journal of medicine, 2016-12, Vol.375 (26), p.2519-2529

2016

Volltextzugriff (PDF)

Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience

British journal of dermatology (1951), 2007-11, Vol.157 (5), p.1050-1051

2007

Volltextzugriff (PDF)

Conceptual Model of Graph-based Individual Tree and Its Utilization in Digital Twin and Metaverse of Urban Forest

International archives of the photogrammetry, remote sensing and spatial information sciences., 2024-10, Vol.XLVIII-4-2024, p.7-12

2024

Volltextzugriff (PDF)

Response Time Optimization for Replica Selection Service in Data Grids

Journal of computer science, 2008-06, Vol.4 (6), p.487-493

2008

Volltextzugriff (PDF)

POS0782-PARE MANAGING PSORIATIC ARTHRITIS: PATIENTS’ VIEWS AND ATTITUDES TO USING AN ONLINE WELLNESS PROGRAM

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.683-683

2023

Volltextzugriff (PDF)

Oral or transdermal opioids for osteoarthritis of the knee or hip

São Paulo medical journal, 2009-11, Vol.127 (6), p.388-388

2009

Volltextzugriff (PDF)

High sensitivity, specificity and predictive value of the Connective Tissue Disease Screening Questionnaire among urban African-American women

Lupus, 2005-01, Vol.14 (10), p.832-836

2005

Volltextzugriff (PDF)

POS0194 MORBIDITY AND MORTALITY OF BREAKTHROUGH COVID-19 IN PATIENTS WITH IMMUNE MEDIATED CONDITIONS ON B CELL DEPLETING THERAPIES AND THE EFFECTS OF MONOCLONAL ANTIBODY TREATMENT

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.330-330

2022

Volltextzugriff (PDF)

P5421Cardiorenal risk of celecoxib compared to naproxen, or ibuprofen in arthritis patients: a sub-analysis of the PRECISION trial

European heart journal, 2018-08, Vol.39 (suppl_1)

2018

Volltextzugriff (PDF)

DOSE ESCALATION AND THE SAFETY OF CELECOXIB, IBUPROFEN, AND NAPROXEN: ANALYSIS OF THE PRECISION TRIAL

Journal of the American College of Cardiology, 2018-03, Vol.71 (11), p.A85-A85

2018

Volltextzugriff (PDF)

POS1103 “WHAT MATTERS”: PATIENT AND CLINICIAN PERSPECTIVES IN PSORIATIC ARTHRITIS CARE

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.879-880

2022

Volltextzugriff (PDF)

AB0966 Are Current Patient Reported Outcomes Tools Optimized to Capture the Entire Patient Experience?

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.1610-1610

2022

Volltextzugriff (PDF)

AB1092 GUSELKUMAB RAPIDLY IMPROVES ACTIVITIES OF DAILY LIVING IN PATIENTS WITH ACTIVE PSA: POOLED ANALYSIS OF 2 PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1768-1769

2023

Volltextzugriff (PDF)

SAT0434 MINIMAL CLINICALLY IMPORTANT DIFFERENCE IN OUTCOME MEASURES FOR USE IN CLINICAL CARE AND PRAGMATIC TRIALS IN PsA

Annals of the rheumatic diseases, 2020-06, Vol.79 (Suppl 1), p.1173-1174

2020

Volltextzugriff (PDF)

POS1060 A PROSPECTIVE, LONGITUDINAL STUDY TO EVALUATE REAL-WORLD PATIENT EXPERIENCES AND TREATMENT SATISFACTION WITH SECUKINUMAB FOR PSORIATIC ARTHRITIS

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.808-809

2021

Volltextzugriff (PDF)

AB1122 GUSELKUMAB VS GOLIMUMAB IN PSA TNFI-INADEQUATE RESPONDERS (EVOLUTION): FORMULATING A PRAGMATIC PHASE 3B RANDOMIZED TRIAL

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1791-1791

2023

Volltextzugriff (PDF)

Effets à long terme sur le profil lipidique du filgotinib (FIL), inhibiteur spécifique de JAK1, dans le traitement du rhumatisme psoriasique : analyse des essais EQUATOR et EQUATOR2

Revue du rhumatisme (Ed. française : 1993), 2020-12, Vol.87, p.A179-A179

2020

Volltextzugriff (PDF)

The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial

The American journal of medicine, 2017-12, Vol.130 (12), p.1415-1422.e4

2017

Volltextzugriff (PDF)

1 – 25 von 268

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(182)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Polycyclic aromatic hydrocarbons and risk of rheumatoid arthritis: a cross-sectional analysis of the National Health and Nutrition Examination Survey, 2007–2016

Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial

AB0045 Activated rnase l as a novel disease activity biomarker in psoriatic arthritis

Psoriatic arthritis screening tools: study design and methodological challenges

Adalimumab for treatment of pyoderma gangrenosum

POS1050 SECUKINUMAB LEADS TO IMPROVEMENT ACROSS PSORIATIC ARTHRITIS MANIFESTATIONS OVER 2 YEARS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR: A POST HOC ANALYSIS OF FUTURE 5

Oral or transdermal opioids for osteoarthritis of the knee or hip

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis

Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience

Conceptual Model of Graph-based Individual Tree and Its Utilization in Digital Twin and Metaverse of Urban Forest

Response Time Optimization for Replica Selection Service in Data Grids

POS0782-PARE MANAGING PSORIATIC ARTHRITIS: PATIENTS’ VIEWS AND ATTITUDES TO USING AN ONLINE WELLNESS PROGRAM

Oral or transdermal opioids for osteoarthritis of the knee or hip

High sensitivity, specificity and predictive value of the Connective Tissue Disease Screening Questionnaire among urban African-American women

POS0194 MORBIDITY AND MORTALITY OF BREAKTHROUGH COVID-19 IN PATIENTS WITH IMMUNE MEDIATED CONDITIONS ON B CELL DEPLETING THERAPIES AND THE EFFECTS OF MONOCLONAL ANTIBODY TREATMENT

P5421Cardiorenal risk of celecoxib compared to naproxen, or ibuprofen in arthritis patients: a sub-analysis of the PRECISION trial

DOSE ESCALATION AND THE SAFETY OF CELECOXIB, IBUPROFEN, AND NAPROXEN: ANALYSIS OF THE PRECISION TRIAL

POS1103 “WHAT MATTERS”: PATIENT AND CLINICIAN PERSPECTIVES IN PSORIATIC ARTHRITIS CARE

AB0966 Are Current Patient Reported Outcomes Tools Optimized to Capture the Entire Patient Experience?

AB1092 GUSELKUMAB RAPIDLY IMPROVES ACTIVITIES OF DAILY LIVING IN PATIENTS WITH ACTIVE PSA: POOLED ANALYSIS OF 2 PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES

SAT0434 MINIMAL CLINICALLY IMPORTANT DIFFERENCE IN OUTCOME MEASURES FOR USE IN CLINICAL CARE AND PRAGMATIC TRIALS IN PsA

POS1060 A PROSPECTIVE, LONGITUDINAL STUDY TO EVALUATE REAL-WORLD PATIENT EXPERIENCES AND TREATMENT SATISFACTION WITH SECUKINUMAB FOR PSORIATIC ARTHRITIS

AB1122 GUSELKUMAB VS GOLIMUMAB IN PSA TNFI-INADEQUATE RESPONDERS (EVOLUTION): FORMULATING A PRAGMATIC PHASE 3B RANDOMIZED TRIAL

Effets à long terme sur le profil lipidique du filgotinib (FIL), inhibiteur spécifique de JAK1, dans le traitement du rhumatisme psoriasique : analyse des essais EQUATOR et EQUATOR2

The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial

Suchergebnisse filtern